VcMMAE Size:Solid 10 mg Smiles: CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@@]21C

Smiles: CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@@]21C

Results demonstrates that the combined use of Celecoxib and fasudil significantly decreases COX-2 and Rho kinase II expression surrounding the lesion site in rats with spinal cord injury

which is only slightly less potent than in bovine serum

are thought to facilitate tumor metastasis

Smiles: O[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)CO

VcMMAE Size:Solid 10 mg Smiles: CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@@]21CVcMMAE is a MMAE derivative with valine citrulline (Vc) linker. VcMMAE can be used to make antibody drug conjugate. VcMMAE is a anti mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine citrulline (vc). Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to